Pharmaceuticals (Basel) . Antigenic Characterization of Neuraminidase of Influenza A/H7N9 Viruses Isolated in Different Years

[tetano]

Pharmaceuticals (Basel)


. 2022 Sep 9;15(9):1127.
doi: 10.3390/ph15091127.
Antigenic Characterization of Neuraminidase of Influenza A/H7N9 Viruses Isolated in Different Years


Yulia Desheva ¹ , Igor Losev ¹ , Nadezhda Petkova ¹ , Polina Kudar ¹ , Svetlana Donina ¹ , Andrey Mamontov ¹ , Chih-Hsuan Tsai ^{2 3} , Yu-Chan Chao ^{2 4 5}



Affiliations

• PMID: 36145348
• DOI: 10.3390/ph15091127

Abstract

Influenza outbreaks caused by A/H7N9 viruses have occurred since 2013. After 2016, A/H7N9 influenza viruses underwent evolutionary changes. In this study, we examined the antigenic properties of influenza neuraminidase (NA) of A/H7N9 viruses as part of a live influenza vaccine (LAIV). It was shown that neuraminidase inhibiting (NI) antibodies obtained after A/Anhui/1/2013(H7N9)-based LAIV vaccination did not inhibit A/Hong Kong/125/2017(H7N9) NA and vice versa. The A/Hong Kong/125/2017(H7N9)-based LAIV elicited higher levels of NI antibodies compared to the A/Anhui/1/2013(H7N9)-based LAIV after two doses. Thelow degree of coincidence of the antibody response to hemagglutinin (HA) and NA after LAIV vaccination allows us to consider an enzyme-linked lectin assay (ELLA) as an additional measure for assessing the immunogenicity of influenza vaccines. In mice, N9-reactive monoclonal antibodies (mABs) for the A/environment/Shanghai/RL01/2013(H7N9) influenza virus partially protected against lung infection from the A/Guangdong/17SF003/2016 IDCDC-RG56N(H7N9) virus, thus showing the cross-protective properties of monoclonal antibodies against the drift variant.

Keywords: antibodies; influenza A/H7N9; live influenza vaccine; monoclonal antibodies; neuraminidase.